Abstract:Cancer targeting gene-viro-therapy (CTGVT) approach has become a hotspot and a trend in the field of cancer biotherapy and oncolytic adenovirus is an ideal vector to carry the targeting genes. In this study, we used human telomerase reverse transcriptase (hTERT) promoter to control the adenovirus early region 1a (E1A) and the human α-fetoprotein (AFP) promoter integrated with hypoxia response element (HRE) to control the adenovirus early region 1b (E1B). Then the novel double-regulated adenovirus Ad-hTERT-HREAF (named SG505) was engineered. The short-hairpin RNA against focal adhesion kinase (FAK) was inserted into SG505 and thus forming Ad-hTERT-HREAF-shRNA (called SG505‑siFAK). Then various oncolytic adenoviruses were examined to verify whether they could suppress liver cancer cells selectively and efficiently both in vitro and in vivo. Both replicative and replication-defective adenoviruses carrying FAK-shRNA significantly inhibited the expression of FAK in Hep3B and SMMC-7721 cell lines and efficiently suppressed the growth of liver cancer cell lines with minor effect to normal cells. Furthermore, the recombined oncolytic adenoviruses, SG505-siFAK, SG505-EGFP and SG505 were able to selectively propagate in AFP-positive liver cancer cells in vitro and the SG505-siFAK efficiently suppressed the expression of FAK. SG505-siFAK showed the most potent tumor inhibition capability among the three recombined adenovirus with IC50 levels of 0.092±0.009 and 0.424±0.414 pfu/cell in the Hep3B and HepG2 cell line, respectively. Animal experiment further confirmed that SG505-siFAK achieved the most significant tumor inhibition of Hep3B liver cancer xenografted growth by intratumoral injection comparing to the intravenous injection among the three recombined viruses. Immunohistochemical results indicated that FAK expression was downregulated significantly in the tumors treated with SG505-siFAK. The dual-regulated oncolytic adenovirus SG505-siFAK was proven to inhibit the growth of liver cancer cells selectively and efficiently, therefore SG505-siFAK could be a potential agent for future clinical trials of hepatocellular carcinoma.

A dual cancer-specific recombinant adenovirus suppresses the growth of liver cancer cells in vivo and in vitro

Anti-tumor effect of a dual cancer-specific recombinant adenovirus on ovarian cancer cells

A novel recombinant adenovirus expressing apoptin and melittin genes kills hepatocellular carcinoma cells and inhibits the growth of ectopic tumor

Gene Therapy Targeting Hepatocellular Carcinoma by A Dual-Regulated Oncolytic Adenovirus Harboring the Focal Adhesion Kinase Shrna

Recombinant Oncolytic Adenovirus Combined with Cyclophosphamide Induces Synergy in the Treatment of Breast Cancer in Vitro and in Vivo

Ad-VT causes ovarian cancer A2780 cell death via mitochondrial apoptosis and autophagy pathways

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

A New Oncolytic Adenoviral Vector Carrying Dual Tumour Suppressor Genes Shows Potent Anti-Tumour Effect

Conditionally Replicative Adenovirus Vector Carrying Trail Gene For Enhanced Oncolysis Of Human Hepatocellular Carcinoma

Oncolytic Adenovirus-Mediated E1A Gene Therapy Induces Tumor-Cell Apoptosis and Reduces Tumor Angiogenesis Leading to Inhibition of Hepatocellular Carcinoma Growth in Animal Model

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo

Combined Use of Chemotherapeutics and Oncolytic Adenovirus in Treatment of AFP-expressing Hepatocellular Carcinoma

Adenovirus-Mediated Combined Anti-Angiogenic and Pro-Apoptotic Gene Therapy Enhances Antitumor Efficacy in Hepatocellular Carcinoma

A comparative study of the ability of recombinant oncolytic adenovirus, doxorubicin and tamoxifen to inhibit the proliferation of breast cancer cells

Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC.

Combination Effect of Oncolytic Adenovirus Therapy and Herpes Simplex Virus Thymidine Kinase/ganciclovir in Hepatic Carcinoma Animal Models.

[Tumor-Targeting Expression of a New Tumor Suppressor Gene HCCS1 and Its Tumor-Selective Inhibitory Effects on Hepatocellular Carcinoma].

Adenovirus-Mediated Il-24 Expression Suppresses Hepatocellular Carcinoma Growth Via Induction of Cell Apoptosis and Cycling Arrest and Reduction of Angiogenesis

Tumor Suppressor in Lung Cancer-1 (TSLC1) Mediated by Dual-Regulated Oncolytic Adenovirus Exerts Specific Antitumor Actions in a Mouse Model